ReviewVirus genes2020
Approaches to optimize therapeutic bacteriophage and bacteriophage-derived products to combat bacterial infections.
Review in Virus genes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Isolation, Identification, and Prophylactic Evaluation of a Newly IsolatedMicroorganisms · 2026Article
- Phage Therapy: Application and Related Problems-A Review.Life (Basel, Switzerland) · 2025Review
- Engineered Phage-Guided Nanotherapeutic Systems for Precision Antibacterial Therapy: Hacking Bacterial Resistance Mechanisms.Pharmaceutics · 2025Review
- Environmental Antimicrobial Resistance: Key Drivers, Hotspots, Innovative Strategies, and Challenges in the Fight Against Superbugs.MicrobiologyOpen · 2025Review
- Phage and enzyme therapies in wound infections: From lab to bedside.Chinese medical journal · 2025Review
- Virological and Pharmaceutical Properties of Clinically Relevant Phages.Antibiotics (Basel, Switzerland) · 2025Article
- Antibiotic Resistance ofPharmaceuticals (Basel, Switzerland) · 2025Review
- Phages as potential life-saving therapeutic option in the treatment of multidrug-resistant urinary tract infections.Acta biochimica Polonica · 2025Review
- Hidden Places for Foodborne Bacterial Pathogens and Novel Approaches to Control Biofilms in the Meat Industry.Foods (Basel, Switzerland) · 2024Review
- Characterization and Comparative Genomic Analysis of vB_BceM_CEP1: A Novel Temperate Bacteriophage Infecting Burkholderia cepacia Complex.Journal of microbiology (Seoul, Korea) · 2024Article
- Pharmacokinetics and Biodistribution of Phages and their Current Applications in Antimicrobial Therapy.Advanced therapeutics · 2024Article
- Review
- Article
- Genetically Engineered Microorganisms and Their Impact on Human Health.International journal of clinical practice · 2024Review
- Bacterial Virus Forcing of Bacterial O-Antigen Shields: Lessons from Coliphages.International journal of molecular sciences · 2023Review
- Phage Therapy-Challenges, Opportunities and Future Prospects.Pharmaceuticals (Basel, Switzerland) · 2023Review
- A Genomic Analysis of theInternational journal of molecular sciences · 2023Article
- Antibacterial activity of epsilon-poly-l-lysine produced byMicrobiology (Reading, England) · 2023Article
- Statistical optimization of a podoviral anti-MRSA phage CCASU-L10 generated from an under sampled repository: Chicken rinse.Frontiers in cellular and infection microbiology · 2023Article
- Isolation and Characterization of a Newly Discovered Phage, V-YDF132, for Lysing Vibrio harveyiViruses · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emerging occurrence of antibiotic-resistant bacterial pathogens leads to a recollection of bacteriophage as antimicrobial therapeutics. This article presents a short overview of the clinical phage application including their use in military medicine and discusses the genotypic and phenotypic properties of a potential "ideal" therapeutic phage. We describe current efforts to engineer phage for their improved usability in pathogen treatment. In addition, phage can be applied for pathogen detection, selective drug delivery, vaccine development, or food and surface decontamination. Instead of viable phage, (engineered) phage-derived enzymes, such as polysaccharide depolymerases or peptidoglycan-degrading enzymes, are considered as promising therapeutic candidates. Finally, we briefly summarize the use of phage for the detection and treatment of "Category A priority pathogens".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.